GSK at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
GSK brings 3 presentations to ASH 2026 in New Orleans, and exhibits at Booth 1739. GSK supports symposia on myelofibrosis, myeloproliferative neoplasms and BCMA-directed antibody-drug conjugates and hosts a theater session on myeloma options in community care. Its research covers belantamab mafodotin.
| Organization | ASH 2026 Attendance |
|---|---|
GSK London, United Kingdom | |
Global pharmaceutical company whose oncology focus includes blood cancers, with medicines for myelofibrosis and multiple myeloma. | Booth Exhibiting at Booth 1739 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 3:00pm–6:00pm A Case-Based Exploration of Current and Future Directions in Myelofibrosis – Where We Are, Where We’re Going Real patient cases showing how experts treat myelofibrosis today, paired with reviews of current data and ongoing research on emerging therapies. Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About BCMA-Directed Antibody-Drug Conjugates and Bispecific Antibodies in Multiple Myeloma – What Clinicians Want To Know Answers to community oncologists' top questions on B-cell maturation antigen-targeted antibody-drug conjugates and bispecific antibodies in multiple myeloma. Poster Sat Dec 12 5:30pm–7:30pm Talk Mon Dec 14 12:15pm–1:15pm |
Find decision makers at GSK
Tell us what you sell and we’ll find the people at GSK most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction